Lantern Pharma posts Q3 net loss of $4.2 million as LP-184 trial meets primary endpoints

Lantern Pharma Inc. reported a net loss of $4.2 million for the third quarter of 2025, compared to a net loss of $4.5 million in the same period of 2024. Net loss per common share, basic and diluted, was $0.39, down from $0.42 in the prior year period. Total operating expenses were $4.3 million, a decrease from $5.2 million in 2024. Cash, cash equivalents, and marketable securities totaled $12.4 million as of September 30, 2025, compared to $24.0 million at the end of 2024. Total assets were $13.6 million, with total liabilities of $4.0 million and stockholders’ equity of $9.6 million. Key business developments for the period included completion of the Phase 1a clinical trial for LP-184, achieving all primary endpoints with a 48% clinical benefit rate in evaluable cancer patients at or above the therapeutic dose threshold. Lantern Pharma also advanced enrollment in the first-in-human clinical trial for LP-284 in non-Hodgkin lymphoma and other cancers, and reported initial clinical data for the Asian cohort in the Harmonic Trial. The company progressed its Starlight Therapeutics subsidiary toward planned Phase 1⁄2 clinical trials and expanded its RADR AI platform, preparing to launch initial modules as open-source AI agents. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lantern Pharma Inc. published the original content used to generate this news brief on November 13, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here